- £53.42m
- £35.83m
- £1.04m
RCS - Angle PLC - Prostate Cancer UK funds new study using Parsortix
AnnouncementREG - Angle PLC - Preliminary Results
AnnouncementREG - Angle PLC - Notice of Preliminary Results and Webcast
AnnouncementRCS - Angle PLC - Poster on Parsortix system presented at AACR 2022
AnnouncementRCS - Angle PLC - Identifying drug targets in cancer metastasis
AnnouncementRCS - Angle PLC - Rapid information on patient response to therapies
AnnouncementRCS - Angle PLC - Identifying therapeutic targets in TNBC patients
AnnouncementRCS - Angle PLC - Update on laboratory accreditation
AnnouncementREG - Angle PLC - Price Monitoring Extension
AnnouncementREG - Angle PLC - Second Price Monitoring Extn
AnnouncementREG - Angle PLC - Holding(s) in Company
AnnouncementREG - AIM - AIM Notice - 24/02/2022
AnnouncementREG - Angle PLC - Issue of Equity
AnnouncementRCS - Angle PLC - Potential in immunotherapy treatment selection
AnnouncementRCS - Angle PLC - Concordance of Parsortix with tissue biopsy
AnnouncementREG - Angle PLC - Update on lab accreditation and ovarian study
AnnouncementRCS - Angle PLC - Insight into drug resistance in NSCLC
AnnouncementREG - Angle PLC - Issue of Equity
AnnouncementREG - Angle PLC - Issue of Equity
Announcement